Sherman EJ - Search Results

1

Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).

Shapiro LQ, Sherman EJ, Riaz N, Setton J, Koutcher L, Zhang Z, Shi W, Fury MG, Wolden SL, Pfister DG, Morris L, Lee N. Shapiro LQ, et al. Among authors: sherman ej. Oral Oncol. 2014 Oct;50(10):947-55. doi: 10.1016/j.oraloncology.2014.07.001. Epub 2014 Aug 11. Oral Oncol. 2014. PMID: 25132089 Free PMC article.

2

Clinical economics of head and neck malignancies.

Sherman EJ, Ruchlin HS, Holden JS, Pfister DG. Sherman EJ, et al. Hematol Oncol Clin North Am. 1999 Aug;13(4):867-81. doi: 10.1016/s0889-8588(05)70098-8. Hematol Oncol Clin North Am. 1999. PMID: 10494519 Review.

3

The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.

Sherman EJ, Pfister DG, Ruchlin HS, Rubin DM, Radzyner MH, Kelleher GH, Slovin SF, Kelly WK, Scher HI. Sherman EJ, et al. Cancer. 2001 Feb 15;91(4):841-53. Cancer. 2001. PMID: 11241254 Clinical Trial.

4

A new intensified therapeutic regimen for advanced head and neck squamous cell carcinomas: where does it fit among available treatment options?

Pfister DG, Sherman EJ, Wolden SL. Pfister DG, et al. Among authors: sherman ej. Cancer Invest. 2001;19(2):217-8. doi: 10.1081/cnv-100000157. Cancer Invest. 2001. PMID: 11296625 No abstract available.

5

Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.

Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Singh B, et al. Head Neck. 2002 May;24(5):437-42. doi: 10.1002/hed.10066. Head Neck. 2002. PMID: 12001073

6

Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.

Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, Scher H, Shah J, Shaha A, Kraus D, Cordon-Cardo C, Pfister DG. Osman I, et al. J Clin Oncol. 2002 Jul 1;20(13):2980-7. doi: 10.1200/JCO.2002.06.161. J Clin Oncol. 2002. PMID: 12089228

7

Using patients as their own controls for cost evaluation of phase I clinical trials.

Sherman EJ, Rubin DM, Venkatraman E, Schwartz GK, Miller VA, Radzyner MH, Ruchlin HS, Spriggs D, Pfister DG. Sherman EJ, et al. J Clin Oncol. 2004 Apr 1;22(7):1308-14. doi: 10.1200/JCO.2004.06.118. J Clin Oncol. 2004. PMID: 15051779 Clinical Trial.

8

Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.

Kramer NM, Horwitz EM, Cheng J, Ridge JA, Feigenberg SJ, Cohen RB, Nicolaou N, Sherman EJ, Babb JS, Damsker JA, Langer CJ. Kramer NM, et al. Among authors: sherman ej. Head Neck. 2005 May;27(5):406-14. doi: 10.1002/hed.20163. Head Neck. 2005. PMID: 15719391 Clinical Trial.

9

Combined modality treatment of squamous cell cancer of the head and neck.

Devlin J, Sherman E. Devlin J, et al. Clin Adv Hematol Oncol. 2005 May;3(5):373-82. Clin Adv Hematol Oncol. 2005. PMID: 16167011 Review.

10

Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma.

Ganly I, Talbot S, Carlson D, Viale A, Maghami E, Osman I, Sherman E, Pfister D, Chuai S, Shaha AR, Kraus D, Shah JP, Socci ND, Singh B. Ganly I, et al. J Clin Oncol. 2007 Apr 10;25(11):1369-76. doi: 10.1200/JCO.2005.05.3397. J Clin Oncol. 2007. PMID: 17416856

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

177 results

Search Page